Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Iovance Biotherapeutics Inc Logo

ARKK Holdings of Iovance Biotherapeutics (IOVA) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
January 18, 2022SELL3.282k0.0004%ARKK
January 12, 2022SELL186.000k0.0188%ARKK
January 6, 2022SELL2.304m0.26%ARKK
January 5, 2022SELL118.825k0.0139%ARKK
January 4, 2022SELL329.582k0.0371%ARKK

Key Statistics

Upcoming EarningsSee Full Calendar
DateFebruary 23, 2022(Est)Revenue
Expected
Actual▫️
EPS
Expected-$0.56
Actual▫️
🕵🏼Found In🏷Last Price
ARKKARKG$14.72
⚖️Weighting🧢Market Cap
0%$2.31b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
410
🏋️‍♀️Weight Rank Across All Funds🌏Country
70🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$29.210%
Description
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.
Website
www.iovance.com

Research Notes and Commentary for IOVA